Waters, Chinese Pharmacopeia Commission Establish Joint Open Laboratory
News Jul 10, 2014
Waters Corporation announce an agreement with the Chinese Pharmacopoeia Commission (ChP) to establish a Joint Open Laboratory.
Scheduled to open before the end of 2014, the new Joint Open Laboratory will focus on in-depth research of pharmacopoeia standards, development of testing methods, methods validations and basic and advanced technical training of pharmacopoeia detection methods. Both the ChP and Waters® expect the laboratory to become one of the national technical support centers in the field of Chinese pharmaceutical standards.
"Waters is very excited about our new collaboration with the Chinese Pharmacopeia Commission," said Art Caputo, President of the Waters Division. "I am confident that this new Joint Open Laboratory will make positive contributions to assuring drug quality control in China, it will quickly become an international leader in the field of traditional Chinese pharmaceutical standards."
At the collaboration agreement signing ceremony in Beijing, Secretary General Zhang Wei of the ChP pointed out that "the ChP-Waters Joint Open Laboratory cooperation would become another milestone of the development of the ChP. This cooperation not only meets the needs of ChP’s own development, but also meets the demands of enhanced pharmacopoeia standards and improved public drug safety."
The laboratory will be outfitted with a full complement of Waters chromatography and mass spectrometry technologies, including (but not limited to) a range of ACQUITY UPLC® systems, ACQUITY UPC2® System, Xevo® tandem quadrupole and time-of-flight mass spectrometers, and a Natural Products Application Solution with UNIFI®.
Agilent Technologies Presents Thought Leader Award to Dr. Ram SasisekharanNews
Agilent Technologies awards Dr. Ram Sasisekharan with the Agilent Thought Leader Award in recognition of his contributions in the field of biologics characterization.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018